retatrutide type 2 diabetes trial results 🚨Breaking: Retatrutide's first Phase 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Today, we shared new data

The GLP-1 component promotes insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite effects well established across the GLP-1 drug class

Best Probiotic for Leaky Gut

In addition to GLP-1 therapy, we offer a range of weight loss and wellness services to complement your treatment and ensure long-term success

Body-weight reduction in obesity (phase 2) A 48-week randomised, double-blind, placebo-controlled phase 2 trial in the New England Journal of Medicine studied retatrutide in 338 adults with obesity

MHRA updates guidance for semaglutide prescribers and patients

Our content may include products that have been independently chosen and recommended by Dr